Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil
Abstract Background The docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen is an effective form of chemotherapy for advanced esophageal cancer. However, the incidence of adverse events such as febrile neutropenia and hematological toxicity is high. Methods Among 937 patients with esophageal canc...
| Published in: | World Journal of Surgical Oncology |
|---|---|
| Main Authors: | Yu Ohkura, Masaki Ueno, Harushi Udagawa |
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-07-01
|
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12957-019-1665-x |
Similar Items
Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim
by: Tomonori Makiguchi, et al.
Published: (2025-06-01)
by: Tomonori Makiguchi, et al.
Published: (2025-06-01)
Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
by: Kosuke Hamai, et al.
Published: (2023-04-01)
by: Kosuke Hamai, et al.
Published: (2023-04-01)
On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status
by: Ivo Abraham, et al.
Published: (2024-01-01)
by: Ivo Abraham, et al.
Published: (2024-01-01)
Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051
by: Keita Miura, et al.
Published: (2024-02-01)
by: Keita Miura, et al.
Published: (2024-02-01)
Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
by: Girma Tekle Gebremariam, et al.
Published: (2022-12-01)
by: Girma Tekle Gebremariam, et al.
Published: (2022-12-01)
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
by: Esse I. H. Akpo, et al.
Published: (2017-09-01)
by: Esse I. H. Akpo, et al.
Published: (2017-09-01)
Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study
by: Youngwoo Jeon, et al.
Published: (2023-03-01)
by: Youngwoo Jeon, et al.
Published: (2023-03-01)
Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study
by: Derek Weycker, et al.
Published: (2019-08-01)
by: Derek Weycker, et al.
Published: (2019-08-01)
Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III
by: Toshimi Takano, et al.
Published: (2023-10-01)
by: Toshimi Takano, et al.
Published: (2023-10-01)
Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
by: Shinya Tsuboi, et al.
Published: (2023-01-01)
by: Shinya Tsuboi, et al.
Published: (2023-01-01)
Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study
by: Wen Zhao, et al.
Published: (2024-08-01)
by: Wen Zhao, et al.
Published: (2024-08-01)
A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
by: Patrick Wayne Cobb, et al.
Published: (2020-09-01)
by: Patrick Wayne Cobb, et al.
Published: (2020-09-01)
Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5‐Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study
by: Ryosuke Kumanishi, et al.
Published: (2025-05-01)
by: Ryosuke Kumanishi, et al.
Published: (2025-05-01)
Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer
by: Motoki Sekikawa, et al.
Published: (2023-12-01)
by: Motoki Sekikawa, et al.
Published: (2023-12-01)
Primary Prophylaxis Lapelga<sup>®</sup> in Early Breast Cancer: A Real-World Experience
by: Fahad Khan, et al.
Published: (2023-03-01)
by: Fahad Khan, et al.
Published: (2023-03-01)
Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis
by: Xia Zhu, et al.
Published: (2023-12-01)
by: Xia Zhu, et al.
Published: (2023-12-01)
Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01)
by: G. D. Petrova, et al.
Published: (2015-12-01)
Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis
by: Shruti Rastogi, et al.
Published: (2021-10-01)
by: Shruti Rastogi, et al.
Published: (2021-10-01)
Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
by: María Alejandra Larrarte-González, et al.
Published: (2023-05-01)
by: María Alejandra Larrarte-González, et al.
Published: (2023-05-01)
How I treat febrile neutropenia
by: Marcio Nucci
Published: (2021-02-01)
by: Marcio Nucci
Published: (2021-02-01)
Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
by: Ga-Young Song, et al.
Published: (2023-10-01)
by: Ga-Young Song, et al.
Published: (2023-10-01)
Febrile Neutropenia Due To Brucellosis: Case Report
by: Abdullah Sakin, et al.
Published: (2012-06-01)
by: Abdullah Sakin, et al.
Published: (2012-06-01)
Clinical Epidemiology Characteristics and Etiology of Febrile Neutropenia in Children: Analysis of 421 Cases
by: Sang Ngoc Nguyen, et al.
Published: (2022-08-01)
by: Sang Ngoc Nguyen, et al.
Published: (2022-08-01)
Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy
by: Maria Bachlitzanaki, et al.
Published: (2023-10-01)
by: Maria Bachlitzanaki, et al.
Published: (2023-10-01)
Febrile Neutropenia in Intensive Care Unit
by: Nattamol Hosiriluck, et al.
Published: (2015-07-01)
by: Nattamol Hosiriluck, et al.
Published: (2015-07-01)
Validation of the CSRFENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6
by: Razan Zatarah, et al.
Published: (2022-10-01)
by: Razan Zatarah, et al.
Published: (2022-10-01)
The use of granulocyte colony-stimulating factors in the management of breast cancer patients
by: Anna Bałata, et al.
Published: (2025-09-01)
by: Anna Bałata, et al.
Published: (2025-09-01)
Evaluation of Febrile Neutropenia in Hematologic Malignancy Patients
by: Müge ASLAN, et al.
Published: (2014-12-01)
by: Müge ASLAN, et al.
Published: (2014-12-01)
The cost effectiveness of the respiratory virus panel in childhood febrile neutropenia
by: Hüsamettin Vatansev, et al.
Published: (2023-03-01)
by: Hüsamettin Vatansev, et al.
Published: (2023-03-01)
Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH
by: Marcio Nucci, et al.
Published: (2024-12-01)
by: Marcio Nucci, et al.
Published: (2024-12-01)
Febrile neutropenia in the emergency department
by: Malle Simeon, et al.
Published: (2021-01-01)
by: Malle Simeon, et al.
Published: (2021-01-01)
Secondary Infections in Cancer Patients with Febrile Neutropenia
by: Alpay Azap, et al.
Published: (2012-08-01)
by: Alpay Azap, et al.
Published: (2012-08-01)
Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis
by: Zühre Kaya, et al.
Published: (2023-08-01)
by: Zühre Kaya, et al.
Published: (2023-08-01)
Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma
by: Mikako Tamba, et al.
Published: (2025-04-01)
by: Mikako Tamba, et al.
Published: (2025-04-01)
Prevalencia de gérmenes con multirresistencia antibiótica en bacteriemia asociada a neutropenia febril en pacientes oncológicos hospitalizados
by: Carlos Soliz Poveda, et al.
Published: (2022-08-01)
by: Carlos Soliz Poveda, et al.
Published: (2022-08-01)
Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors
by: Dimitrijević Jelena, et al.
Published: (2022-01-01)
by: Dimitrijević Jelena, et al.
Published: (2022-01-01)
Chemotherapy Induced Neutropenia, Febrile-Neutropenia and Determinants Among Solid Cancer Patients Attending Oncology Unit of a Tertiary Care Teaching Hospital in Ethiopia
by: Dessalegn M, et al.
Published: (2023-02-01)
by: Dessalegn M, et al.
Published: (2023-02-01)
Thrombin generation in children with febrile neutropenia
by: Ayça Koca Yozgat, et al.
Published: (2021-04-01)
by: Ayça Koca Yozgat, et al.
Published: (2021-04-01)
Doente com Neutropenia Febril: Uma Intervenção Especializada – Revisão Integrativa da Literatura
by: Cristina Santos, et al.
Published: (2021-06-01)
by: Cristina Santos, et al.
Published: (2021-06-01)
Uso do dispositivo Pegfilgrastim OBI para prevenção de neutropenia: revisão de escopo
by: Vivian do Prado Martins, et al.
Published: (2023-08-01)
by: Vivian do Prado Martins, et al.
Published: (2023-08-01)
Similar Items
-
Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim
by: Tomonori Makiguchi, et al.
Published: (2025-06-01) -
Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
by: Kosuke Hamai, et al.
Published: (2023-04-01) -
On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status
by: Ivo Abraham, et al.
Published: (2024-01-01) -
Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051
by: Keita Miura, et al.
Published: (2024-02-01) -
Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
by: Girma Tekle Gebremariam, et al.
Published: (2022-12-01)
